ArticleFrontiers in medicine2026
Splenic infarction after endoscopic glue injection for gastric varices: proportion, exploratory correlates, and clinical outcomes from a propensity score-matched analysis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Splenic infarction after endoscopic cyanoacrylate injection for gastric varices (GV) is poorly characterized. We estimated its proportion among computed tomography (CT)-evaluable patients and explored clinical features and short-term outcomes. Methods: We retrospectively screened 255 adult patients undergoing endoscopic glue injection for GV between January 2018 and February 2025. Eligible patients had CT within 30 days and no pre-existing infarction or alternative causes; imaging was clinically selected rather than protocol-mandated. Expanded 1:4 propensity score matching included clinical, laboratory, and index-session endoscopic features. Exploratory Firth regression addressed sparse events and complete separation. Results: Of 183 CT-evaluable patients, 16 (8.7%) had radiologically confirmed splenic infarction. After matching, 16 cases and 64 controls were analyzed, although residual imbalance remained. All cases had ≥2 previous injection sessions versus 15.6% of matched controls, producing complete separation; the Firth estimate was therefore not considered a stable effect size. Exploratory models showed statistical signals for repeated injections, larger splenic diameter, large spontaneous portosystemic shunts, and greater index-session glue volume. These features may represent advanced portal hypertension and treatment complexity rather than independent risk factors. Most cases (93.8%) were managed conservatively. Thirty-day mortality and rebleeding did not differ, whereas hospital stay was longer (median, 14 vs. 10 days; Conclusions: Splenic infarction was identified in 8.7% of this selected CT-evaluable cohort. The observed features should be regarded as exploratory clinical markers, not causal or actionable predictors. Imaging selection, residual imbalance, 16 events, complete separation, and wide uncertainty preclude incidence estimation, precise effect-size interpretation, or individual risk prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.